American Journal of Cardiology
Volume 103, Issue 2 , Pages 227-231 , 15 January 2009

Differential Use of Warfarin for Secondary Stroke Prevention in Patients With Various Types of Atrial Fibrillation

  • William R. Lewis, MD

      Affiliations

    • MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio
    • Corresponding Author InformationCorresponding author: Tel: 216-778-2349; fax: 216-778-3927
    • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • University of California, Los Angeles, Los Angeles, California
    • ,
  • Kenneth A. LaBresh, MD

      Affiliations

    • Masspro, Waltham, Massachusetts
    • ,
  • Christopher P. Cannon, MD

      Affiliations

    • Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • ,
  • Wenqin Pan, PhD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
    • ,
  • Dennis M. Super, MD

      Affiliations

    • MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio
    • ,
  • Suzanne A. Sorof, MD

      Affiliations

    • MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio
    • ,
  • Lee H. Schwamm, MD

      Affiliations

    • Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts

Received 11 May 2008 ,Revised 28 August 2008 ,Accepted 28 August 2008.

References 

  1. Roe MT. Success stories: how hospitals are improving care. Am Heart J. 2004;148(suppl):S52–S55
  2. LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm LH. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the “Get With The Guidelines” program. Arch Intern Med. 2008;168:411–417
  3. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy (Stroke Prevention in Atrial Fibrillation Investigators). J Am Coll Cardiol. 2000;35:183–187
  4. Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (Analysis of pooled data from five randomized controlled trials). Arch Intern Med. 1994;154:1449–1457
  5. Marcu CB, Ghantous AE, Caracciolo EA, Donohue TJ. Patterns of anticoagulation in patients hospitalized with atrial fibrillation: warfarin is underused in paroxysmal atrial fibrillation. Conn Med. 2003;67:595–598
  6. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? (Report from the Stockholm Cohort-Study on Atrial Fibrillation (SCAF-Study)). Eur Heart J. 2006;27:1954–1964
  7. Barthélémy JC, Feasson-Gerard S, Garnier P, Gaspoz JM, Da Costa A, Michel D, et al. Automatic cardiac event recorders reveal paroxysmal atrial fibrillation after unexplained strokes or transient ischemic attacks. Ann Noninvasive Electrocardiol. 2003;8:194–199
  8. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–1840
  9. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833
  10. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018–3026
  11. Lim MJ, Roychoudhury C, Baker PL, Bossone E, Mehta RH. Differences in quality of care among patients hospitalized with atrial fibrillation as primary or secondary cause for admission. Int J Qual Health Care. 2005;17:255–258
  12. Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med. 2006;119:607–615
  13. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375

 The data analysis of this study was performed by the Duke Clinical Research Institute, Durham, North Carolina, and funded by the American Heart Association, Dallas Texas. Dr. Super was supported by Grant No. M01 RR000080 from the National Center for Research Resources, National Institutes of Health, Bethesda, Maryland. Dr. Lewis has received speaker honoraria from Reliant Pharmaceuticals. Dr. Fonarow has received research grants from GlaxoSmithKline and honoraria from GlaxoSmithKline, Merck, Schering-Plough, and Bristol Myers Squibb and is or has been a consultant for Glaxo-Smith-Kline, Schering-Plough, Merck, and Bristol Myers Squibb. Dr. Cannon has received research grants from Accumetrics, AstraZeneca, Bristol-Myers Squibb, Glaxo Smith Kline, Merck, Sanofi-Aventis, and Schering Plough.

PII: S0002-9149(08)01581-6

doi: 10.1016/j.amjcard.2008.08.062

American Journal of Cardiology
Volume 103, Issue 2 , Pages 227-231 , 15 January 2009

Article Tools

* Image Usage & Resolution